Abstract
To evaluate the efficacy of a new agent, palonosetron, in Hodgkin Lymphoma patients treated with ABVD regimen. Complete response during the overall phase of the first ABVD cycle, was the primary endpoint. Secondary end points were: emesis-free patients and use of rescue medication during the acute and overall phases. From January 2008 to February 2009 36 patients were enrolled. The primary endpoint (CR 0-120 h) was achieved by 55.6% patients. In conclusion our study demonstrated that a single dose of palonosetron plus a single dose of dexamethasone was effective in preventing CINV in patients treated with ABVD regimen.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Antiemetics / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Bleomycin / adverse effects
-
Dacarbazine / adverse effects
-
Dexamethasone / administration & dosage*
-
Doxorubicin / adverse effects
-
Drug Therapy, Combination
-
Female
-
Hodgkin Disease / drug therapy*
-
Humans
-
Isoquinolines / administration & dosage*
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Nausea / prevention & control*
-
Palonosetron
-
Prospective Studies
-
Quinuclidines / administration & dosage*
-
Serotonin Antagonists / administration & dosage
-
Treatment Outcome
-
Vinblastine / adverse effects
-
Vomiting / chemically induced
-
Vomiting / prevention & control*
-
Young Adult
Substances
-
Antiemetics
-
Isoquinolines
-
Quinuclidines
-
Serotonin Antagonists
-
Bleomycin
-
Palonosetron
-
Vinblastine
-
Dacarbazine
-
Dexamethasone
-
Doxorubicin